NCT06990269

Phase 2 Study of ADX-038 in Participants With Geographic Atrophy

A Phase 2, Randomized, Masked, Placebo-Controlled Study of Subcutaneously Administered ADX-038 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 240 (estimated)
• Sponsor: ADARx Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 60 Years
• Healthy volunteers: Not accepted

Summary

Phase 2 study is designed to assess the efficacy of ADX-038 compared with placebo in participants with GA secondary to AMD. Safety, pharmacokinetics (PK), and pharmacodynamics (PD) will also be assessed.

Conditions

• Geographic Atrophy Secondary to Age-related Macular Degeneration

Interventions

Type	Name	Description
DRUG	ADX-038	siRNA duplex oligonucleotide
DRUG	Placebo	Saline

Timeline

• Start date: 2025-11-10
• Primary completion: 2027-09-30
• Completion: 2027-12-01
• First posted: 2025-05-25
• Last updated: 2026-03-02

Locations

17 sites across 3 countries: United States, Australia, Canada

Regulatory

• FDA-regulated drug study